Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Kineta nets $1.5M in SBIR grant
August 2016
SHARING OPTIONS:

SEATTLE—Biotechnology company Kineta Inc. has been awarded a “direct to Phase 2” SBIR grant of up to $1.5 million over two years from the National Institute of Allergy and Infectious Disease (NIAID), which will help advance the development of compounds that trigger the RIG-I pathway, activate IRF-3 and induce an antiviral response. The company’s screening platform helps to identify novel innate immune antivirals and vaccine adjuvants, and Kineta is exploring broad-spectrum antivirals for respiratory and emerging viruses in its work with NIAID.
 
“We are pleased to broaden our longstanding collaboration with the NIAID to advance lead optimization of our novel immune modulating compounds,” Dr. Shawn Iadonato, CEO of Kineta, remarked in a press release. “These new lead compounds that were identified from Kineta’s AViiD screening platform hold tremendous potential to fill significant unmet medical needs in infectious diseases.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.